NetFlix Inc vs Sana Biotechnology Inc — how do they compare? NetFlix Inc trades at $68.16 (market cap $281.48B), while Sana Biotechnology Inc trades at $3.17 (market cap $873.84M). The key difference: NetFlix Inc is far larger — about 322.1× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, NetFlix Inc nearer its low. Which is the better fit depends on your goals.
| NFLX | SANA | |
|---|---|---|
Market Cap | $281.48B | $873.84M |
Sector | Consumer Cyclical | Health |
52-Week High | $126.33 | $5.92 |
52-Week Low | $67.60 | $2.68 |
Enterprise Value | $286.66B | $848.03M |
Signals from Pluang's Aura AI — not financial advice
Netflix (NFLX) is trading at $68.95, down 7.26% over 24 hours and approaching its 52-week low. The stock shows bearish technical signals with oversold RSI levels, while fundamentals remain strong with Q1 2026 EPS beating expectations at $1.23 versus $0.763. Revenue grew to $45.18B in 2025 with a net income margin of 24.3%, though valuation ratios like P/E of 21.26 and P/S of 6.02 suggest moderate pricing. Recent news highlights stock declines despite business growth, with focus on advertising expansion and content performance.
The outlook for NFLX is mixed; strong earnings and ad-tier scalability offer upside, but technical weakness and competitive pressures pose risks. Analysts maintain a buy consensus with a $90.47 price target, implying significant potential appreciation. Key risks include market sentiment shifts and execution challenges in new revenue streams, requiring careful monitoring of quarterly results and subscriber trends.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →